Skip to content

Study · Randomized controlled trial · n = 15 · 2020

9 results

Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes.

Dubé MC, D'Amours M, Weisnagel SJ

Diabetes, obesity & metabolism6 May 2020Cited by 17 (Europe PMC)

PMID32250534 (opens in a new tab)DOI10.1111/dom.14050 (opens in a new tab)PepBankPUB-32250534
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide decreased total ad libitum food intake versus placebo.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide reduced total food intake compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal ad libitum food intake
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    When treated with liraglutide, participants modified their ad libitum food consumption with decreased total intake and % fat and increased carbohydrates.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide decreased the percentage of fat in ad libitum food intake versus placebo.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide lowered the share of fat in food eaten compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePercentage of fat in food intake
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    When treated with liraglutide, participants modified their ad libitum food consumption with decreased total intake and % fat and increased carbohydrates.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide increased carbohydrate intake in the ad libitum meal versus placebo.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide raised carbohydrate intake in a free meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseCarbohydrate intake
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    When treated with liraglutide, participants modified their ad libitum food consumption with decreased total intake and % fat and increased carbohydrates.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide significantly reduced fasting desire to eat versus placebo.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide reduced the fasting desire to eat compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting desire to eat
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Their appetite sensations were modified: fasting desire to eat, hunger and prospective food consumption were significantly reduced.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide significantly reduced hunger versus placebo.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide reduced hunger compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHunger
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Their appetite sensations were modified: fasting desire to eat, hunger and prospective food consumption were significantly reduced.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide significantly reduced prospective food consumption versus placebo.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide reduced how much food people expected to eat, compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseProspective food consumption
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Their appetite sensations were modified: fasting desire to eat, hunger and prospective food consumption were significantly reduced.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide prolonged the sensation of fullness for a few hours after a standardized breakfast.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide made the feeling of fullness last longer after breakfast.

    Peptide
    Liraglutide
    Outcome
    IncreaseSensation of fullness after breakfast
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The sensation of fullness was prolonged for a few hours after a standardized breakfast.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide significantly reduced restraint score versus placebo.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide reduced the restraint score of eating behaviour compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseDietary restraint
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Restraint and disinhibition were significantly reduced by liraglutide.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In overweight or obese people with type 1 diabetes on insulin, liraglutide significantly reduced disinhibition score versus placebo.

    In plain wordsIn overweight people with type 1 diabetes, liraglutide reduced the disinhibition score of eating behaviour compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseDisinhibition
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    titrated from 0.6 to 1.2 to 1.8 mg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Restraint and disinhibition were significantly reduced by liraglutide.
    1 context sentence
    Summary · context
    In a double-blinded crossover fashion, 15 participants were randomly assigned (1:1) to receive placebo or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.